Forbion Capital Partners, a Dutch life-sciences venture capital firm, said it led the closing of a C$13.5 million (US$10.85 million) series B financing round for Engene Inc., of Vancouver, Brish Columbia, with a syndicate of life science investors including existing shareholder, Merck Lumira Biosciences Fund, and new investors, Fonds de Solidarité FTQ and Inbio Ventures (Luxembourg).